Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming

The impact of EGFR-mutant NSCLC precision therapy is limited by acquired resistance despite initial excellent response. Classic studies of EGFR-mutant clinical resistance to precision therapy were based on tumor rebiopsies late during clinical tumor progression on therapy. Here, we characterized a n...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Thiagarajan, Praveena S., Wu, Xiaoliang, Zhang, Wei, Shi, Ivy, Bagai, Rakesh, Leahy, Patrick, Feng, Yan, Veigl, Martina, Lindner, Daniel, Danielpour, David, Yin, Lihong, Rosell, Rafael, Bivona, Trever G., Zhang, Zhenfeng, Ma, Patrick C.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Priority Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5347670/
https://ncbi.nlm.nih.gov/pubmed/27852038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13307
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados